Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61K - Preparations for medical, dental, or toilet purposes › A61K 9 - Medicinal preparations characterised by special physical form
Patents for A61K 9 - Medicinal preparations characterised by special physical form (299,044)
05/2012
05/31/2012WO2012068962A1 Use of compound salvia miltiorrhiza preparation in preparing medicament for resisting pulmonary hypertension
05/31/2012WO2012068958A1 Antianxiety and sleep disorder improving use of albiflorin or metabolite thereof in
05/31/2012WO2012068783A1 Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
05/31/2012WO2012068780A1 Gelatin microsphere for pharmaceutical use and preparation method thereof
05/31/2012WO2012068670A1 Binding drugs with nanocrystalline cellulose (ncc)
05/31/2012WO2012047870A3 Antimicrobial preservation of propofol emulsions
05/31/2012WO2012046994A3 Nitric oxide delivery system using thermosensitive synthetic polymers
05/31/2012WO2012046009A8 Composition for intraocular implantation of bevacizumab
05/31/2012WO2012040595A9 Administration of serine protease inhibitors to the stomach
05/31/2012WO2012040224A3 Oral composition and method of forming and using same
05/31/2012WO2012037648A8 Process for chelating copper ions using cb-te2a bifunctional chelate
05/31/2012WO2012036983A3 Removal of toxins from gastrointestinal fluids
05/31/2012WO2012036430A3 Non-aqueous oily injectable formulation exhibiting preservative efficacy
05/31/2012WO2012027411A9 Compositions and uses of materials with high antimicrobial activity and low toxicity
05/31/2012WO2012023142A3 Functional food compositions and methods
05/31/2012WO2012021735A8 Pharmaceutical products from fungal strains
05/31/2012WO2012016683A3 Oral dosage form of pregabalin
05/31/2012WO2012012772A3 Drug eluting hydrogels for catheter delivery
05/31/2012WO2012011740A3 Method for preparing microspheres and microspheres produced thereby
05/31/2012WO2012007729A3 Pharmaceutical compositions comprising r (+) budesonide and one or more bronchodilators
05/31/2012WO2012006298A3 Formulation for co-therapy treatment of diabetes
05/31/2012WO2012003290A3 Dental composites comprising nanoparticles of amorphous calcium phosphate
05/31/2012WO2011163136A3 Tuned multifunctional magnetic nanoparticles for biomedicine
05/31/2012WO2011158034A3 Coating compositions and methods of obtaining thereof
05/31/2012WO2011156045A3 Tablet formulation of ezatiostat
05/31/2012WO2011151018A3 Orodispersible tablets of erythritol and isomalt
05/31/2012WO2011148209A3 Use of diatomaceous earth in the pharmaceutical industry
05/31/2012WO2011147926A3 Magnetically responsive membrane structures
05/31/2012WO2011146858A3 Foams, including microcellular foams, containing colloidal particulates
05/31/2012WO2011139595A3 Elongated biodegradable depot for sustained drug release to treat chronic pelvic pain
05/31/2012WO2011139253A3 Pharmaceutical compositions comprising ceftibuten
05/31/2012WO2011121034A3 Water-free pharmaceutical compositions suitable for local anaesthetics
05/31/2012WO2011101868A4 Stable pharmaceutical preparations containing clindamycin and benzoyl peroxide and method thereof
05/31/2012WO2011063776A3 Soluble beta-glucan-api complexes for pharmaceutical use
05/31/2012US20120135940 Pharmaceutical compositions for lipophilic drugs
05/31/2012US20120135376 Collagen Biomaterial Wedge
05/31/2012US20120135086 Method of tissue repair using a composite material
05/31/2012US20120135082 Extended release compositions comprising as active compound venlafaxine hydrochloride
05/31/2012US20120135081 Hydrophobins for dispersing active agents
05/31/2012US20120135079 Modified Release Tranexamic Acid Formulation
05/31/2012US20120135078 Angina treatment
05/31/2012US20120135077 Abuse resistant opioid drug-ion exchange resin complexes having hybrid coatings
05/31/2012US20120135076 Intrabuccally rapidly disintegrating tablet and a production method of the tablets
05/31/2012US20120135075 Dosage form
05/31/2012US20120135074 High-Strength Testosterone Undecanoate Compositions
05/31/2012US20120135073 Oral Drug Delivery System
05/31/2012US20120135072 Oral Drug Delivery System
05/31/2012US20120135071 Abuse-proofed dosage form
05/31/2012US20120135070 Copolymers
05/31/2012US20120135069 Nanonized testosteron formulations for improved bioavailability
05/31/2012US20120135068 Liposome-encapsulated glutathione for oral administration
05/31/2012US20120135067 Vaccine for mycoplasma infection
05/31/2012US20120135066 Regulators of the hedgehog pathway, compositions and uses related thereto
05/31/2012US20120135065 Amphoteric Liposomes, A Method Of Formulating An Amphoteric Liposome And A Method Of Loading An Amphoteric Liposome
05/31/2012US20120135064 Conjugated nanodelivery vehicles
05/31/2012US20120135063 Glucuronic acid-containing glucan, process for production of same, and use of same
05/31/2012US20120135061 Pary-xylene based microfilm elution devices
05/31/2012US20120135055 Dry Powder Inhaler Formulations
05/31/2012US20120135054 Poly (Ester Ether Amide)s and Uses Thereof
05/31/2012US20120135053 Nanoparticulate telmisartan compositions and process for the preparation thereof
05/31/2012US20120135052 Method for preparing an organic-compatible and water-compatible composition of metal nanocrystals, and resulting composition
05/31/2012US20120135051 Generation of vascularized human heart tissue and uses thereof
05/31/2012US20120135050 Extended-release formulation for reducing the frequency of urination and method of use thereof
05/31/2012US20120135049 Decellularized tissue engineered constructs and tissues
05/31/2012US20120135048 novel formulation of indomethacin
05/31/2012US20120135047 Novel formulation of diclofenac
05/31/2012US20120135046 Corticosteroid particles and method of production
05/31/2012US20120135045 Antimicrobial Collagenous Constructs
05/31/2012US20120134967 Scaffolds For Cell Transplantation
05/31/2012US20120134958 Hydroxyethyl starch-containing polypeptide compositions
05/31/2012US20120134956 Colloidal metal compositions and methods
05/31/2012US20120134935 Use of mometasone furoate for treating airway passage and lung disease
05/31/2012US20120134934 Glycine derivatives and medicinal compositions thereof
05/31/2012US20120134926 Charge-dynamic polymers and delivery of anionic compounds
05/31/2012US20120134925 Application and Uses of PRG4 and Therapeutic Modulation Thereof
05/31/2012US20120134919 Ion substituted calcium phosphate particles
05/31/2012US20120132218 Smokeless tobacco cessation product
05/31/2012US20120132204 Unit dose dry powder inhaler
05/31/2012DE102010052847A1 Verfahren zur Herstellung einer PPI-haltigen pharmazeutischen Zubereitung A process for the preparation of a pharmaceutical preparation containing PPI-
05/31/2012CA2856101A1 Immunomodulatory compositions
05/31/2012CA2818894A1 Protein delivery from stem cell microcarriers
05/31/2012CA2818565A1 Pediatric formulation
05/31/2012CA2818194A1 Solid dosage forms of oleyl phosphocholine
05/31/2012CA2817177A1 Fast disintegrating compositions comprising nabilone and randomly methylated beta cyclodextrin
05/31/2012CA2816883A1 Therapeutic methods and compositions for solid delivery
05/31/2012CA2816288A1 Compositions of rotigotine, derivatives thereof, or pharmaceutically acceptable salts of rotigotine or its derivative
05/31/2012CA2816216A1 Binding drugs with nanocrystalline cellulose (ncc)
05/30/2012EP2457592A1 Microneedle array
05/30/2012EP2457591A2 Dendritic pic micelles with bioactive proteins
05/30/2012EP2457590A2 Protein formulation
05/30/2012EP2457589A1 Reverse targeting lipid vesicle
05/30/2012EP2457581A1 Composition for external preparation for skin
05/30/2012EP2457570A1 Fentanyl-containing adhesive preparation for external use
05/30/2012EP2457568A1 Composition comprising an avermectine and metronidazole in particular for treating rosacea
05/30/2012EP2457565A1 Transdermal therapeutic system containing rotigotin
05/30/2012EP2457564A1 Controlled release formulations of octreotide
05/30/2012EP2457563A1 Zero-order modified release solid dosage forms
05/30/2012EP2457562A1 Zero-order modified release solid dosage forms
05/30/2012EP2457561A1 Tablet having hollow structure
05/30/2012EP2457560A1 Topical compositions
1 ... 504 505 506 507 508 509 510 511 512 513 514 515 516 517 518 519 520 521 522 523 524 ... 2991